Gynesonics adds more than $6 million to its coffers as it looks to bring its VizAblate minimally invasive fibroid device to the U.S. market.
Gynesonics added another $6.3 million to its coffers as it looks to bring the latest iteration of its VizAblate fibroid device to the U.S. market.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1xSZtzM
Cap comentari:
Publica un comentari a l'entrada